Given this increased expression, anti-NECTIN4 ADCs were trialed in bladder, breast, lung and pancreatic cancers and have demonstrated responses in preclinical xenograft models (Challita-Eid et al., 2016). The gene discussed is NECTIN4; the disease is pancreatic neoplasm.